AKTS · Aktis Oncology, Inc.

Aktis Oncology, a clinical-stage biotechnology company, continued its development trajectory in Q1 FY2026, generating $3.2M in revenue while investing heavily in its pipeline, resulting in operating income of -$22.7M and net income of -$18.3M, or diluted EPS of $-0.38. These results align with the company's strategy to advance product candidates through clinical development, as management notes expectations for rising research and development expenses to support pipeline progression.

Since inception, Aktis has incurred significant operating losses, consistent with its clinical-stage focus. Liquidity remains a core focus, with management directing investors to detailed sections on capital resources and risk factors. The company acknowledges potential challenges in raising additional funds on favorable terms, emphasizing prudent cash management amid ongoing burn. These Q1 results demonstrate execution on pipeline priorities while navigating public market realities, positioning Aktis to sustain development momentum.